Natera Full Year 2024 Earnings: Beats Expectations

Advertisement

Natera (NASDAQ:NTRA) Full Year 2024 Results

Key Financial Results

  • Revenue: US$1.70b (up 57% from FY 2023).
  • Net loss: US$190.4m (loss narrowed by 56% from FY 2023).
  • US$1.53 loss per share (improved from US$3.78 loss in FY 2023).
earnings-and-revenue-growth
NasdaqGS:NTRA Earnings and Revenue Growth March 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Natera Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 9.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Natera you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:NTRA

Natera

A diagnostics company, provides molecular testing services worldwide.

Flawless balance sheet with reasonable growth potential.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5371.1% undervalued
31 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HE
PLY logo
HegelBayeBagel on PlaySide Studios ·

PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Fair Value:AU$0.8465.5% undervalued
7 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.275.7% undervalued
10 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
TH
CGNT logo
TheValueDetector on Cognyte Software ·

This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti

Fair Value:US$95.6792.6% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

CO
composite32
FRU logo
composite32 on Freehold Royalties ·

Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.

Fair Value:CA$19.3811.9% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
UN
unknown
GFI logo
unknown on Gold Fields ·

Beyond the "Value Trap"—Defending the $50 Intrinsic Floor

Fair Value:US$64.219.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
UN
unknown
TSM logo
unknown on Taiwan Semiconductor Manufacturing ·

The "Geopolitical Discount" vs. The Monopolistic Floor: The Two Narratives of TSM

Fair Value:US$42814.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.4% undervalued
59 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3638.3% undervalued
45 users have followed this narrative
19 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2234.2% undervalued
1278 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement